IN8bio, Inc. Files 8-K Report
Ticker: INAB · Form: 8-K · Filed: Oct 27, 2025 · CIK: 1740279
| Field | Detail |
|---|---|
| Company | In8bio, Inc. (INAB) |
| Form Type | 8-K |
| Filed Date | Oct 27, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-filing, company-information
TL;DR
IN8bio, Inc. updated its 8-K filing with new address details.
AI Summary
On October 27, 2025, IN8bio, Inc. filed an 8-K report. The filing indicates the company's principal executive offices are located at 350 5th Avenue, Suite 5330, New York, NY 10118. The company was formerly known as Incysus Therapeutics, Inc. until May 10, 2018.
Why It Matters
This filing provides updated corporate information and addresses for IN8bio, Inc., which is important for investors and stakeholders to ensure they have the correct contact and identification details for the company.
Risk Assessment
Risk Level: low — This is a routine corporate filing with no new financial or operational information that would indicate increased risk.
Key Players & Entities
- IN8bio, Inc. (company) — Registrant
- Incysus Therapeutics, Inc. (company) — Former company name
- May 10, 2018 (date) — Date of name change
- October 27, 2025 (date) — Date of report
- 350 5th Avenue, Suite 5330, New York, NY 10118 (address) — Principal executive offices
FAQ
What is the primary purpose of this 8-K filing?
This 8-K filing serves as a current report for IN8bio, Inc., primarily updating corporate information such as its principal executive offices and former company name.
When was the report filed?
The report was filed on October 27, 2025.
What was IN8bio, Inc.'s former name?
IN8bio, Inc.'s former name was Incysus Therapeutics, Inc.
On what date did the company change its name?
The company's name change from Incysus Therapeutics, Inc. to IN8bio, Inc. occurred on May 10, 2018.
Where are IN8bio, Inc.'s principal executive offices located?
IN8bio, Inc.'s principal executive offices are located at 350 5th Avenue, Suite 5330, New York, New York 10118.
Filing Stats: 457 words · 2 min read · ~2 pages · Grade level 11 · Accepted 2025-10-27 08:01:22
Key Financial Figures
- $0.0001 — ange on which registered Common Stock, $0.0001 par value per share INAB The Nasdaq
Filing Documents
- d65132d8k.htm (8-K) — 25KB
- d65132dex991.htm (EX-99.1) — 17KB
- 0001193125-25-250756.txt ( ) — 163KB
- inab-20251027.xsd (EX-101.SCH) — 3KB
- inab-20251027_lab.xml (EX-101.LAB) — 18KB
- inab-20251027_pre.xml (EX-101.PRE) — 11KB
- d65132d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 99.1 Press Release, dated October 27, 2025 101 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IN8bio, Inc. Date: October 27, 2025 By: /s/ Patrick McCall Patrick McCall Chief Financial Officer and Secretary (Principal Financial and Accounting Officer)